Aptose Biosciences appoints Fletcher Payne as SVP and CFO with $430k base salary and 1M option grant

Aptose Biosciences Inc.

Appointment effective June 27, 2022; Payne reports to CEO.
Base salary of $430,000; eligible for annual discretionary bonus up to 40% of base.
Subject to board approval, granted options to purchase 1,000,000 common shares.
Severance: without cause or for good reason – one year salary lump sum, average bonus, COBRA up to 12 months.
Payne previously CFO at Synapse, Catalyst Bioscience, CytomX, Plexxikon, and others.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fletcher Payne

Senior Vice President and Chief Financial Officer

APTOF · Aptose Biosciences Inc.

Effective: 2022-06-27
Filed: June 28, 2022, 7:59 PM ET

On June 27, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Mr. Fletcher Payne as its Senior Vice President and Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fletcher Payne was appointed as Senior Vice President and Chief Financial Officer at Aptose Biosciences Inc..

Action: appointed
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

On June 27, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Mr. Fletcher Payne as its Senior Vice President and Chief Financial Officer.

View on SEC.gov

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-004578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.